Acquired Immunodeficiency Syndrome, Extrapulmonary Tuberculosis, Human Immunodeficiency Virus (HIV), Tuberculosis, Pulmonary
Conditions
Keywords
Point-of-care systems, Tuberculosis/Diagnosis, Biomarkers/Urin, Lipopolysaccharides/urine, Audit intervention, Diagnostic tests/Routine, Ultrasound, Bedside, Biobank, Stepped wedge cluster randomised trial, Multicenter study, Audit and feedback, Ghana, Adult, Hospitalization
Brief summary
Tuberculosis (TB) remains the major cause of morbidity and mortality among patients with HIV. Sub-optimal diagnostics contributes towards poor patient outcome and there is an urgent need to identify non-sputum-based point-of-care diagnostic tests. The urine based lateral flow lipoarabinomannan TB diagnostic test (LF-LAM) is a simple, inexpensive point-of-care test. In 2015, the World Health Organization endorsed LF-LAM for conditional use among patients with advanced HIV, but uptake of the test in clinical practices has been poor. The investigators aim to identify point-of-care (POC) strategies that can improve TB case detection and clinical outcomes among patients with advanced HIV. The project includes a main study and two sub-studies. The main study is a multicenter stepped wedge cluster-randomized controlled trial of LF-LAM implementation among patients with advanced HIV with 8-weeks follow-up. LF-LAM will be added to standard care and implemented stepwise at three hospitals in Ghana. Education in national TB treatment guidelines in collaboration with the Tuberculosis Control programme in Ghana, and Clinical audit of clinical staff with feedback, will be used to assess and strengthen LF-LAM implementation. The primary outcome time to TB treatment, for which a sample size of 690 participants will provide \>90% power to detect a minimum of 7 days reduction. Secondary outcomes are: TB related morbidity, TB case detection, time to TB diagnosis and overall early mortality at 8 weeks. The HIV-associated TB epidemiology including genotypic analyses of M. tuberculosis isolates obtained through the main study will be described. In sub study A, focused ultrasound of lungs, heart and abdomen will be performed in a sub cohort of 100 participants. In sub study B, the investigators will establish a biobank and data warehouse for storage of blood, urine and sputum samples collected from participants that enter the study at Korle-Bu Teaching hospital. It is expected that LF-LAM will lead to earlier diagnosis and treatment of TB. Findings may further guide scaling-up of LF-LAM. The HIV-associated epidemic including genotypic properties and resistance properties which is important for improved management will be detailed. The investigators further expect to evaluate the potential of bedside ultrasound as a clinical tool in management of HIV/TB co-infected patients. The unique Ghanaian HIV-cohort and biobank may facilitate rapid evaluation of future prognostic biomarkers and new point-of-care TB diagnostic tests.
Interventions
DIAGNOSTIC_TESTLF-LAM
Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
Sponsors
Odense University Hospital
National Tuberculosis Control Programme, Ghana
Odense Patient Data Explorative Network
University of Ghana
Tema General Hospital, Ghana
Lekma Hospital, Ghana
Korle-Bu Teaching Hospital, Ghana
University of Southern Denmark
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Open label multi-center stepped wedge cluster-randomized controlled implementation trial of the use of urine-based LF-LAM in addition to routine sputum-based TB diagnostic tests to guide initiation of TB treatment among adult hospitalized patients with advanced HIV. The design offers a randomised method of evaluation of the intervention at cluster level. Applying the stepped wedge design ensures that all participating HIV/ART clinic attached wards will have received the intervention at the end of the study period, and provides the basis for the LF-LAM test to become an integrated part of TB health care services also after the project finishes. Clinic staff will be trained on how to use and interpret the LF-LAM test and in TB diagnostic guidelines as outlined by WHO. An Audit and feedback study will identify leaky steps in the TB diagnostic pathway and further strengthen the implementation and possible impact of the LF-LAM test.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-positive * 18 years and above * Able to give informed consent * Admitted at the wards attached to the research site ART/HIV-clinic * Eligible for LF-LAM testing (defined by WHO in the LF-LAM policy update 2019): CD4-cell-count ≤200 cells/μL (the last measured CD4-cell-count); or a WHO clinical stage 3 or 4 event at presentation for care; or seriously ill defined by WHO (respiratory rate \> 30/min, temperature \> 39°C, heart rate \> 120/min or unable to walk unaided); or a positive WHO TB symptom screening including one of the following symptoms: current cough, fever, weight loss, or night sweats
Exclusion criteria
* Anti-tuberculous treatment including preventive treatment with Isoniazide within the last 60 days * Earlier participation in the same study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to TB treatment initiation | 8 weeks follow up | Time to TB treatment initiation defined by time from TB diagnosis suspected to start of anti-tuberculous treatment provided. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| TB related morbidity | 8 weeks follow up | The difference in the proportion of TB patients with reduced TB morbidity score at 8 weeks follow up using The Bandim tuberculosis score with grading 0-13, where a reduction in the score may be used as a measurement of clinical improvement. |
| TB case detection | 8 weeks follow up | Defined as proportion of patients with (i) microbiologically confirmed TB diagnosis and (ii) clinically confirmed TB diagnosis |
| Time to TB diagnosis | 8 weeks follow up | — |
| Time to all-cause mortality. | 8 weeks follow up | Mortality rates during follow up. Underpowered |
Countries
Ghana
Outcome results
None listed